MacroGenics, Inc.

NASDAQ:MGNX

Biotechnology

Healthcare
$1.97 +2.02%

+$0.08 today

Market cap
$125.90M
Beta
1.20
P/E (TTM)
-3.6
EPS (TTM)
-$1.11
52W Low $1.19High $4.64

Volume 0.72M

Average 0.98M

MGNX Interest Income

Income earned on cash, deposits, and investments held by the company.

MacroGenics, Inc.NASDAQ: MGNX

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $1.55M fell 7.4% year over year, ahead of the -29.4% change in trailing-twelve-month interest income. Sequentially, it rose 8.1% from the prior quarter. Over 3 fiscal years it compounded at +26.0% a year.

Context

  • Interest income amounted to 2.3% of revenue in FY2025, down 4.1 pp from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -7.4% holds above the trailing-twelve-month pace of -29.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.55M+8.1% QoQ
Last fiscal yearDec 2025
$3.4M-63.9% YoY
LTMMar 2026
$5.93M-29.4% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.4%——
1 year-63.9%——
3-year CAGR+26.0%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
3.4M USD
Year-over-year change
-63.9%
4-year CAGR
+49.5%

Interest Income vs competitors

How MGNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -29.4% is the 4th highest of 8, against a peer median of -41.9%.
  • Interest income amounts to 3.8% of revenue for MGNX, versus a peer median of 109.5%.
MGNX Competitors
Interest Income for MGNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$16.15M USD+417.4%-12.8%—
WHWKWhitehawk Therapeutics IncLTM Mar 2026$6.77M USD+97.1%+37.5%—
MGNXMacroGenics, Inc.LTM Mar 2026$5.93M USD-29.4%+26.0%3.8%
CNTXContext Therapeutics Inc.LTM Mar 2026$2.94M USD-26.6%+83.4%—
CNTBConnect Biopharma Holdings LimitedFY2025$2.27M USD-49.1%+13.2%3543.8%
IFRXInflaRx N.V.LTM Mar 2026€1.62M EUR-41.9%+42.8%5520.1%
STTKShattuck Labs, Inc.LTM Mar 2026$779K USD-84.9%+19.3%77.9%
CLNNClene Inc.LTM Mar 2026$189K USD-67.8%—141.0%
OVIDOvid Therapeutics Inc.LTM Mar 2026$0 USD——0.0%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
COYACoya Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding MGNX) —-41.9%+28.4%109.5%

Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.64M150.02M57.19M148.34M149.5M
Cost of Revenue2.65M7.38M8.22M12.3M43.18M
Gross Profit72.99M142.63M48.97M136.04M106.32M
Gross Margin96.5%95.1%85.6%91.7%71.1%
Research & Development214.58M207.03M166.58M177.19M140M
Selling, General & Admin63.01M58.95M52.19M71.05M39.16M
Operating Expenses275.79M264.05M217.22M246.62M179.16M
Depreciation & Amortization11.26M11.87M9.65M7.54M7.17M
EBITDA(190.86M)(107.89M)2.02M(57.37M)(59.61M)
EBITDA Margin-252.3%-71.9%3.5%-38.7%-39.9%
Operating Income(202.8M)(121.42M)(168.24M)(110.58M)(72.84M)
Operating Margin-268.1%-80.9%-294.2%-74.5%-48.7%
Interest Income680K1.7M9.69M9.42M3.4M
Interest Expense001.43M1.12M8.51M
Other Income / Expenses680K1.66M159.19M44.56M(2.45M)
Income Before Tax(202.12M)(119.76M)(9.06M)(66.02M)(75.29M)
Pre-Tax Margin-267.2%-79.8%-15.8%-44.5%-50.4%
Income Tax Expense000944K(672K)
Net Income(202.12M)(119.76M)(9.06M)(66.97M)(74.62M)
Net Margin-267.2%-79.8%-15.8%-45.1%-49.9%
EPS (Basic)(3.18)(1.95)(0.15)(1.07)(1.18)
EPS (Diluted)(3.18)(1.95)(0.15)(1.07)(1.18)
Weighted Avg Shares59.94M61.41M61.93M62.62M63.16M
Weighted Avg Shares (Diluted)59.94M61.43M61.93M62.62M63.16M

MacroGenics, Inc.

NASDAQ:MGNX

Intrinsic Alpha fair value

Locked

Current Price

$1.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.